Share This Article:

Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis

Abstract Full-Text HTML XML Download Download as PDF (Size:609KB) PP. 1151-1161
DOI: 10.4236/jct.2015.613125    2,064 Downloads   2,472 Views  

ABSTRACT

Background: Since advanced hepatocellular carcinoma (HCC) is potentially fatal, and patients’ quality of life (QOL) often deteriorates during their treatment, improving the prognosis and QOL of patients given chemotherapy is very important. In addition, cost-effective treatments are highly desirable when chemotherapy must be given repeatedly. The aim of this study was to evaluate the efficacy and usefulness of 5-fluorouracil (5-FU) and high-concentration cisplatin by short-term hepatic arterial infusion chemotherapy (3-day FPL) in advanced HCC patients. Methods: Thirty patients with unresectable advanced HCC were enrolled. The patients underwent hepatic arterial infusion chemotherapy via the implanted port system with 5-FU on days 1 - 3 and a fine-powder formulation of cisplatin in suspended pre-warmed lipiodol on day 2 every 4 to 10 weeks. Tumor response was assessed one month later with CT. Results: All patients had evidence of portal vein invasion (Vp2-4). Four patients achieved a complete response (CR), 8 patients achieved a partial response (PR), and 7 patients had stable disease (SD). The median progression-free survival (PFS) and overall survival (OS) were 198 days and 452 days, respectively. The OS was significantly longer in the successful disease control group (CR, PR, and SD) than in the progressive disease group (P < 0.005). Conclusions: Three-day FPL was effective and tolerable in advanced HCC patients due to its shorter time of administration than conventional FP therapy. Therefore, repetitive 3-day FPL appears useful and contributes to improving the prognosis and QOL of patients with advanced HCC. In addition, this protocol is a cost-effective treatment.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Yata, Y. , Namikawa, M. , Ohyama, T. , Ohsaki, T. , Kanda, D. , Hatanaka, T. , Shibuya, K. , Kubota, J. , Takagi, H. , Takahara, T. and Yoshinaga, T. (2015) Efficacy of 5-Fluorouracil and High-Concentration Cisplatin Suspended in Lipiodol by Short-Term Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Cancer Therapy, 6, 1151-1161. doi: 10.4236/jct.2015.613125.

References

[1] Jermal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011) Global Cancer Statics. CA: A Cancer Journal for Clinicians, 61, 69-90.
http://dx.doi.org/10.3322/caac.20107
[2] El-Serag, H.B. (2012) Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma. Gastroenterology, 142, 1264-1273.
http://dx.doi.org/10.1053/j.gastro.2011.12.061
[3] Llovert, J.M., Bustamante, J., Castells, A., et al. (1999) Natural History of Untreated Nonsurgical Hepatocellular Carcinoma. Rationale for the Design and Evaluation of Therapeutic Trials. Hepatology, 29, 62-67.
http://dx.doi.org/10.1002/hep.510290145
[4] Bruix, J., Sherman, M., Llovet, J.M., et al. (2001) Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL Conference. Journal of Hepatology, 35, 421-430.
http://dx.doi.org/10.1016/S0168-8278(01)00130-1
[5] Maluccio, M. and Covey, A. (2012) Recent Progress in Understanding, Diagnosing, and Treating Hepatocellular Carcinoma. CA: A Cancer Journal for Clinicians, 62, 394-399.
http://dx.doi.org/10.3322/caac.21161
[6] Llovet, J.M., Ricci, S., Mazzaferro, V., et al. (2008) SHARP Investigators Study Group. Sorafenib in Advanced Hepatocellular Carcinoma. The New England Journal of Medicine, 359, 378-390.
http://dx.doi.org/10.1056/NEJMoa0708857
[7] Han, K.H., Lee, J.T. and Seong, J. (2002) Treatment of Non-Resectable Hepatocellular Carcinoma. Journal of Gastroenterology and Hepatology, 17, S424-S427.
http://dx.doi.org/10.1046/j.1440-1746.17.s3.39.x
[8] Bruix, J. and Llovert, J.M. (2002) Prognostic Prediction and Treatment Strategy in Hepatocellular Carcinoma. Hepatology, 35, 519-524.
http://dx.doi.org/10.1053/jhep.2002.32089
[9] Seno, H., Ito, K., Kojima, K., et al. (1999) Efficacy of an Implanted Drug Delivery System for Advanced Hepatocellular Carcinoma Using 5-Fluorouracil, Epirubicin and Mitomycin C. Journal of Gastroenterology and Hepatology, 14, 811-816.
http://dx.doi.org/10.1046/j.1440-1746.1999.01956.x
[10] Atiq, O.T., Kemeny, N., Niedzwiecki, D. and Boter, J. (1992) Treatment of Unresectable Primary Liver Cancer with Intrahepatic Fluorodeoxyuridine and Mitomycin C through an Implantable Pump. Cancer, 69, 920-924.
http://dx.doi.org/10.1002/1097-0142(19920215)69:4<920::AID-CNCR2820690414>3.0.CO;2-Y
[11] Murata, K., Shiraki, K., Kawakita, T., et al. (2003) Low-Dose Chemotherapy of Cisplatin and 5-Fluorouracil or Doxorubin via Implanted Fusion Port for Unresectable Hepatocellular Carcinoma. Anticancer Research, 23, 1719-1722.
[12] Ando, E., Tanaka, M., Yamashita, F., et al. (2002) Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: Analysis of 48 Cases. Cancer, 95, 588-595.
http://dx.doi.org/10.1002/cncr.10694
[13] Itamoto, T., Nakahara, T., Tashiro, H., et al. (2002) Hepatic Arterial Infusion of 5-Fluorouracil and Cisplatin for Unresectable or Recurrent Hepatocellular Carcinoma with Tumor Thrombus of the Portal Vein. Journal of Surgical Oncology, 80, 143-148.
http://dx.doi.org/10.1002/jso.10116
[14] Tanioka, H., Tsuji, A., Morita, S., et al. (2003) Combination Chemotherapy with Continuous 5-Fluorouracil and Low-Dose Cisplatin Infusion for Advanced Hepatocellular Carcinoma. Anticancer Research, 23, 1891-1897.
[15] Kim, B.K., Park, J.Y., Choi, H.J., et al. (2011) Long-Term Clinical Outcomes of Hepatic Arterial Infusion Chemotherapy with Cisplatin with or without 5-Fluorouracil in Locally Advanced Hepatocellular Carcinoma. Journal of Cancer Research and Clinical Oncology, 137, 659-667.
http://dx.doi.org/10.1007/s00432-010-0917-5
[16] Kondo, M., Morimoto, M., Numata, K., Nozaki, A. and Tanaka, K. (2011) Hepatic Arterial Infusion Therapy with a Fine Powder Formulation of Cisplatin for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Japanese Journal of Clinical Oncology, 41, 69-75.
http://dx.doi.org/10.1093/jjco/hyq145
[17] Nagamatsu, H., Hiraki, M., Mizukami, N., et al. (2010) Intra-Arterial Therapy with Cisplatin Suspension in Lipiodol and 5-Fluorouracil for Hepatocellular Carcinoma with Portal Vein Tumour Thrombosis. Alimentary Pharmacology & Therapeutics, 32, 543-550.
http://dx.doi.org/10.1111/j.1365-2036.2010.04379.x
[18] Yamasaki, T. and Sakaida, I. (2012) Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma and Future Treatments for the Poor Responders. Hepatology Research, 42, 340-348.
[19] Nouso, K., Miyahara, K., Uchida, D., et al. (2013) Effect of Hepatic Arterial Infusion Chemotherapy of 5-Fluorouracil and Cisplatin for Advanced Hepatocellular Carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. British Journal of Cancer, 109, 1904-1907.
[20] Song do, S., Song, M.J., Bae, S.H., et al. (2015) A Comparative Study between Sorafenib and Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Journal of Gastroenterology, 50, 445-454.
http://dx.doi.org/10.1007/s00535-014-0978-3
[21] Kudo, M., Chung, H., Haji, S., et al. (2004) Validation of a New Prognostic Staging System for Hepatocellular Carcinoma: The JIS Score Compared with the CLIP Score. Hepatology, 40, 1396-1405.
http://dx.doi.org/10.1002/hep.20486
[22] Therasse, P., Arbuck, S.G., Eisenhauer, E.A., et al. (2000) New Guidelines to Evaluate the Response to Treatment in Solid Tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92, 205-216.
http://dx.doi.org/10.1093/jnci/92.3.205
[23] Cheng, A.L., Kang, Y.K., Chen, Z., et al. (2009) Efficacy and Safety of Sorafenib in Patients in the Asia-Pacific Region with Advanced Hepatocellular Carcinoma: A Phase III Randomised, Double-Blind, Placebo-Controlled Trial. Lancet Oncology, 10, 25-34.
http://dx.doi.org/10.1016/S1470-2045(08)70285-7
[24] Toyoda, H., Nakano, S., Kumada, F., et al. (1995) The Efficacy of Continuous Local Arterial Infusion of 5-Fluorouracil and Cisplatin through an Implanted Reservoir for Severe Advanced Hepatocellular Carcinoma. Oncology, 52, 295-299.
http://dx.doi.org/10.1159/000227477
[25] Okuda, K., Tanaka, M., Shibata, J., et al. (1999) Hepatic Arterial Infusion Chemotherapy with Continuous Low Dose Administration of Cisplatin and 5-Fluorouracil for Multiple Recurrence of Hepatocellular Carcinoma after Surgical Treatment. Oncology Reports, 6, 587-591.
http://dx.doi.org/10.3892/or.6.3.587
[26] Park, J.Y., Ahn, S.H., Yoon, Y.J., et al. (2007) Repetitive Short-Course Hepatic Arterial Infusion Chemotherapy with High-Dose 5-Fluorouracil and Cisplatin in Patients with Advanced Hepatocellular Carcinoma. Cancer, 110, 129-137.
http://dx.doi.org/10.1002/cncr.22759
[27] Moriguchi, M., Takayama, T., Nakamura, M., et al. (2010) Phase I/II Study of a Fine-Powder Formulation of Cisplatin for Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma. Hepatology Research, 40, 369-375.
http://dx.doi.org/10.1111/j.1872-034X.2009.00606.x
[28] Yamashita, Y., Taketomi, A., Itoh, S., et al. (2010) Phase I/II Study of the Lipiodolization Using DDP-H (CDDP Powder; IA-Call) in Patients with Unresectable Hepatocellular Carcinoma. Cancer Chemotherapy and Pharmacology, 65, 301-307.
http://dx.doi.org/10.1007/s00280-009-1034-5
[29] Yodono, H., Matsuo, K. and Shinohara, A. (2011) A Retrospective Comparative Study of Epirubicin-Lipiodol Emulsion and Cisplatin-Lipiodol Suspension for Use with Transcatheter Arterial Chemoembolization for Treatment of Hepatocellular Carcinoma. Anticancer Drugs, 22, 277-282.
http://dx.doi.org/10.1097/CAD.0b013e328342231d
[30] Kora, S., Urakawa, H., Mitsufuji, T., et al. (2013) Warming Effect on Miriplatin-Lipiodol Suspension as a Chemotherapeutic Agent for Transarterial Chemoembolization for Hepatocellular Carcinoma: Preliminary Clinical Experience. CardioVascular and Interventional Radiology, 36, 1023-1029.
http://dx.doi.org/10.1007/s00270-012-0537-3
[31] Woo, H.Y., Bae, S.H., Park, J.Y., et al. (2010) A Randomized Comparative Study of High-Dose and Low-Dose Hepatic Arterial Infusion Chemotherapy for Intractable, Advanced Hepatocellular Carcinoma. Cancer Chemotherapy and Pharmacology, 65, 373-382.
http://dx.doi.org/10.1007/s00280-009-1126-2
[32] Yata, Y., Xue, F., Takahara, T., et al. (2010) Docetaxel Inhibits Progression of Human Hepatoma Cell Line in Vitro and Is Effective in Advanced Hepatocellular Carcinoma. Hepatology Research, 40, 304-310.
http://dx.doi.org/10.1111/j.1872-034X.2009.00598.x

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.